Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 50mg 60tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 70mg 56tk; 70mg 60tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 80mg 30tk; 80mg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 140mg 30tk; 140mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukeemia, lümfotsüütne, krooniline, b-rakk - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - tsütomegaloviiruse infektsioonid - viirusevastased ravimid süsteemseks kasutamiseks - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). tuleks arvesse võtta ametlikke juhiseid sobiva kasutamise kohta viirusevastane ained.

Euroopa Liit - eesti - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemilised preparaadid - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.